{
  "id": 127114,
  "name": "ASTRAZENECA",
  "slug": "astrazeneca",
  "state": null,
  "description": null,
  "totalSpending": 1800000,
  "filings": 29,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 200000
    },
    {
      "year": 2019,
      "income": 100000
    },
    {
      "year": 2020,
      "income": 240000
    },
    {
      "year": 2021,
      "income": 240000
    },
    {
      "year": 2022,
      "income": 240000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 180000
    },
    {
      "year": 2025,
      "income": 360000
    }
  ],
  "firms": [
    "TIBER CREEK GROUP"
  ],
  "lobbyists": [
    "JONATHON JONES",
    "JOHN GONZALEZ",
    "SEAN RICHARDSON",
    "COREY MALMGREN",
    "TIMOTHY ROBINSON",
    "JOHN TWOMEY",
    "DANIEL ZAWITOSKI"
  ],
  "issues": [
    "HCR",
    "MMM",
    "TRD",
    "CPT",
    "FOR",
    "BUD",
    "ENV",
    null
  ],
  "sampleDescriptions": [
    "S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing and transparency. Issues regarding asthma/severe asthma/Family Asthma Act. Issues relating to 340b pricing.",
    "Issues relating to pharmaceutical pricing and transparency, HR 2550 Medicare Telehealth Parity Act of 2017. P.L. 115-123 - Bipartisan Budget Act of 2018, provisions relating to Part D coverage Gap.",
    "Issues related to pharmaceutical pricing and transparency. Issues relating to 340b pricing.",
    "Issues relating to Medicare Part D coverage Gap.",
    "Issues related to pharmaceutical pricing and transparency.",
    "Issues relating to Medicare Part D coverage gap. Issues relating to Part B pricing reform.",
    "Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. Issues related to promoting value based arrangements in Medicare. Proposal to eliminate Medicaid inflationary cap.\nS.474 - SPIKE Act of 2019\nS. 476 - C-Thru Act of 2019\nS.475 -Rx Cap Act of 2019\nS.62 - Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019.",
    "Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. Issues related to promoting value based arrangements in Medicare. Proposal to eliminate Medicaid inflationary cap. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019.",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) -  drug pricing issues.",
    "Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. Issues related to promoting value based arrangements in Medicare. Proposal to eliminate Medicaid inflationary cap. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) -  drug pricing issues.",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) -  drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; Issues related to Covid-19 vaccine development",
    "Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. Issues related to promoting value based arrangements in Medicare. Proposal to eliminate Medicaid inflationary cap. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) -  drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; Issues related to Covid-19 vaccine development. Issues relating to the 340B program and drug pricing legislation;  Executive Order on Lowering Drug Prices by Putting America First",
    "Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. Issues related to Covid-19 vaccine development. Executive Order on Lowering Drug Prices by Putting America First. H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act; Issues related to the Medicaid Drug Rebate Program",
    "Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act; Issues related to the Medicaid Drug Rebate Program",
    "Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.",
    "Issues related to pharmaceutical pricing and transparency; Issues related to Covid-19 vaccine development.",
    "Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform; Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs; H.R.1319 - American Rescue Plan Act of 2021, SEC. 9816, SUNSET OF LIMIT ON MAXIMUM REBATE AMOUNT FOR SINGLE SOURCE DRUGS AND INNOVATOR MULTIPLE SOURCE DRUGS.",
    "S. 1435 - Affordable Prescriptions for Patients Act of 2021; H.R. 2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 80,
  "trajectory": "growing",
  "yearsActive": 8,
  "avgAnnualSpending": 225000,
  "peakYear": 2025,
  "lobbyistCount": 7,
  "firmCount": 1,
  "issueCount": 7
}